Weight loss drugs slash risk of 4 types of cancer by 50% or more, study finds

Key Points:

• The use of GLP-1 medications like Ozempic and Wegovy has surged, primarily for weight loss and type 2 diabetes management, with a 155% increase in diabetic patients using these drugs from 2018 to 2022.
• A new study analyzing over 229,000 obese, non-diabetic individuals found that GLP-1 users had a 41% lower overall risk of developing obesity-related cancers, including a notable 58% reduction in endometrial cancer risk.
• Researchers suggest the cancer risk reduction may result from both weight loss and direct effects of GLP-1 on cancer cells, though causation has not been established and further mechanistic studies are needed.
• Experts caution that while results are promising, the observational study's short median follow-up of two years and potential confounding factors require more long-term, controlled research before GLP-1s can be recommended for cancer prevention.
• Given the widespread and growing use of GLP-1 drugs, understanding their full biological effects is essential, as even modest cancer risk reductions could have significant public health implications.